Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Research square·2026

Same author

A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials.

Biological psychiatry·2025

Same author

Non-V600E BRAF mutations and treatment for hairy cell leukemia.

Blood·2024

Same author

Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.

Leukemia·2024

Same author

Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.

Frontiers in immunology·2023

Same author

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: <i>JACC: CardioOncology</i> State-of-the-Art Review.

JACC. CardioOncology·2023

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Galiximab: a review.

Seema Bhat¹, Myron S Czuczman

¹Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Expert Opinion on Biological Therapy

|January 23, 2010

Summary

Galiximab, an anti-CD80 monoclonal antibody (mAb), shows promise for treating B-cell lymphomas, offering an alternative for patients resistant to rituximab. Further clinical trials are evaluating its potential in various treatment settings.

Area of Science:

Oncology
Immunology
Hematology

Background:

Rituximab resistance is a significant challenge in B-cell lymphoma treatment.
CD80 is a viable target antigen on lymphoma cells, offering potential antitumor activity.
Monoclonal antibodies (mAbs) targeting novel antigens are crucial for overcoming resistance.

Purpose of the Study:

To review preclinical and clinical data on galiximab, an anti-CD80 mAb.
To explore the potential of CD80 as a therapeutic target in B-cell lymphomas.
To update on the clinical development and potential role of galiximab in lymphoma treatment.

Main Methods:

Literature review of PubMed (1975-2009) and major hematology/lymphoma conference abstracts.
Analysis of preclinical data on galiximab's antitumor activity.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: Jun 16, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Review of available clinical trial data for galiximab.

Main Results:

Preclinical studies demonstrate galiximab's efficacy as a single agent and in combination with rituximab.
Galiximab exhibits antitumor activity in various B-cell lymphoma models.
Clinical data, though preliminary, are encouraging for galiximab's therapeutic potential.

Conclusions:

Galiximab is a promising anti-CD80 mAb for B-cell lymphoma treatment.
It is being investigated in both initial and relapsed settings.
Galiximab may become an important addition to future lymphoma treatment strategies.